Neuroprotection in Schizophrenia and Its Therapeutic Implications (original) (raw)

1. Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J Clin Psychiatry 2006;67:983-990. PMID: 16848659.

2. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19-28. PMID: 17199051.

3. Monteiro LC, Silva VA, Louza MR. Insight, cognitive dysfunction and symptomatology in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008;258:402-405. PMID: 18437275.

4. Ibrahim HM, Tamminga CA. Treatment of cognitive dysfunction in schizophrenia. Curr Pharm Biotechnol 2012;13:1587-1594. PMID: 22283754.

5. Hanson E, Healey K, Wolf D, Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep 2010;12:563-571. PMID: 20821286.

6. Webber MA, Marder SR. Better pharmacotherapy for schizophrenia: what does the future hold. Curr Psychiatry Rep 2008;10:352-358. PMID: 18627675.

7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. PMID: 16172203.

8. Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl) 2011;214:89-106. PMID: 20949351.

9. Brown AS. Exposure to prenatal infection and risk of schizophrenia. Front Psychiatry 2011;2:63PMID: 22131978.

10. Bersani G, Quartini A, Manuali G, Iannitelli A, Pucci D, Conforti F, et al. Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study. Neuroradiology 2009;51:363-371. PMID: 19214492.

11. Murray RM, Reveley AM, McGuffin P. Genetic vulnerability to schizophrenia. Psychiatr Clin North Am 1986;9:3-16. PMID: 3515330.

12. Delisi LE. Searching for the true genetic vulnerability for schizophrenia. Genome Med 2009;1:14PMID: 19348701.

13. Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001;98:11650-11655. PMID: 11573002.

14. Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 1998;155:1285-1287. PMID: 9734557.

15. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002;277:29355-29358. PMID: 12072446.

16. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci 1995;57:1011-1026. PMID: 7658909.

17. Vitkovic L, Bockaert J, Jacque C. “Inflammatory” cytokines: neuromodulators in normal brain? J Neurochem 2000;74:457-471. PMID: 10646496.

18. Seguin JA, Brennan J, Mangano E, Hayley S. Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration. Neuropsychiatr Dis Treat 2009;5:5-14. PMID: 19557094.

19. Samuelsson AM, Jennische E, Hansson HA, Holmang A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol 2006;290:R1345-R1356. PMID: 16357100.

20. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006;32:200-202. PMID: 16469941.

21. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010;167:261-280. PMID: 20123911.

22. Gilmore JH, Fredrik Jarskog L, Vadlamudi S, Lauder JM. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004;29:1221-1229. PMID: 15085088.

23. Emsley JG, Mitchell BD, Kempermann G, Macklis JD. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol 2005;75:321-341. PMID: 15913880.

24. Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol 1965;124:319-335. PMID: 5861717.

25. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-1317. PMID: 9809557.

26. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005;28:223-250. PMID: 16022595.

27. Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 2010;11:339-350. PMID: 20354534.

28. Leuner B, Gould E, Shors TJ. Is there a link between adult neurogenesis and learning. Hippocampus 2006;16:216-224. PMID: 16421862.

29. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 2012;64:671-677. PMID: 22006178.

30. Kempermann G. Why new neurons? Possible functions for adult hippocampal neurogenesis. J Neurosci 2002;22:635-638. PMID: 11826092.

31. Jensen O, Lisman JE. Hippocampal sequence-encoding driven by a cortical multi-item working memory buffer. Trends Neurosci 2005;28:67-72. PMID: 15667928.

32. DeCarolis NA, Eisch AJ. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 2010;58:884-893. PMID: 20060007.

33. Vollmayr B, Mahlstedt MM, Henn FA. Neurogenesis and depression: what animal models tell us about the link. Eur Arch Psychiatry Clin Neurosci 2007;257:300-303. PMID: 17401725.

34. Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon? Biol Psychiatry 2004;56:146-150. PMID: 15271582.

35. Duman RS. Depression: a case of neuronal life and death. Biol Psychiatry 2004;56:140-145. PMID: 15271581.

36. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994;6:348-357. PMID: 7841806.

37. Barch DM. What can research on schizophrenia tell us about the cognitive neuroscience of working memory? Neuroscience 2006;139:73-84. PMID: 16300901.

38. Frantseva MV, Fitzgerald PB, Chen R, Moller B, Daigle M, Daskalakis ZJ. Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb Cortex 2008;18:990-996. PMID: 17855721.

39. Weinberger DR. Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 1999;45:395-402. PMID: 10071707.

40. Vita A, De Peri L, Silenzi C, Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006;82:75-88. PMID: 16377156.

41. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001;11:520-528. PMID: 11732705.

42. Sigurdsson T, Stark KL, Karayiorgou M, Gogos JA, Gordon JA. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 2010;464:763-767. PMID: 20360742.

43. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006;11:514-522. PMID: 16415915.

44. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006;52:139-153. PMID: 17015232.

45. Parnet P, Kelley KW, Bluthe RM, Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. J Neuroimmunol 2002;125:5-14. PMID: 11960635.

46. Haour F, Jafarian-Tehrani M, Gabellec MM, Crumeyrolle-Arias M, Hu Y, Wick G, et al. Interleukin-1 receptor defect in autoimmune NZB mouse brain. Ann N Y Acad Sci 1998;840:755-761. PMID: 9629302.

47. Barrientos RM, Higgins EA, Biedenkapp JC, Sprunger DB, Wright-Hardesty KJ, Watkins LR, et al. Peripheral infection and aging interact to impair hippocampal memory consolidation. Neurobiol Aging 2006;27:723-732. PMID: 15893410.

48. Arai K, Matsuki N, Ikegaya Y, Nishiyama N. Deterioration of spatial learning performances in lipopolysaccharide-treated mice. Jpn J Pharmacol 2001;87:195-201. PMID: 11885968.

49. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 2008;105:751-756. PMID: 18178625.

50. Kuzumaki N, Ikegami D, Imai S, Narita M, Tamura R, Yajima M, et al. Enhanced IL-1beta production in response to the activation of hippocampal glial cells impairs neurogenesis in aged mice. Synapse 2010;64:721-728. PMID: 20336624.

51. Wu MD, Hein AM, Moravan MJ, Shaftel SS, Olschowka JA, O'Banion MK. Adult murine hippocampal neurogenesis is inhibited by sustained IL-1beta and not rescued by voluntary running. Brain Behav Immun 2012;26:292-300. PMID: 21983279.

52. Kaneko N, Kudo K, Mabuchi T, Takemoto K, Fujimaki K, Wati H, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006;31:2619-2626. PMID: 16823390.

53. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819. PMID: 9143707.

54. Holmberg KH, Patterson PH. Leukemia inhibitory factor is a key regulator of astrocytic, microglial and neuronal responses in a low-dose pilocarpine injury model. Brain Res 2006;1075:26-35. PMID: 16458863.

55. Kerr BJ, Patterson PH. Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp Neurol 2004;188:391-407. PMID: 15246839.

56. Watanabe Y, Hashimoto S, Kakita A, Takahashi H, Ko J, Mizuno M, et al. Neonatal impact of leukemia inhibitory factor on neurobehavioral development in rats. Neurosci Res 2004;48:345-353. PMID: 15154680.

57. Okahisa Y, Ujike H, Kunugi H, Ishihara T, Kodama M, Takaki M, et al. Leukemia inhibitory factor gene is associated with schizophrenia and working memory function. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:172-176. PMID: 19879916.

58. Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005;25:8217-8228. PMID: 16148229.

59. Turrin NP, Rivest S. Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity. J Neurosci 2006;26:143-151. PMID: 16399681.

60. Pitossi F, del Rey A, Kabiersch A, Besedovsky H. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 1997;48:287-298. PMID: 9169855.

61. Munoz-Fernandez MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998;56:307-340. PMID: 9770242.

62. Sheng W, Zong Y, Mohammad A, Ajit D, Cui J, Han D, et al. Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA-IIA expression in astrocytes and microglia. J Neuroinflammation 2011;8:121PMID: 21943492.

63. Yang L, Lindholm K, Konishi Y, Li R, Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002;22:3025-3032. PMID: 11943805.

64. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004;279:32869-32881. PMID: 15155767.

65. Ben-Hur T, Ben-Menachem O, Furer V, Einstein O, Mizrachi-Kol R, Grigoriadis N. Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol Cell Neurosci 2003;24:623-631. PMID: 14664813.

66. Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 2001;98:1782-1791. PMID: 11535512.

67. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006;26:9703-9712. PMID: 16988041.

68. Chen J, Jacobs-Helber SM, Barber DL, Sawyer ST. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor. Exp Cell Res 2004;298:155-166. PMID: 15242770.

69. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4:1116-1122. PMID: 11600888.

70. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, et al. Control of synaptic strength by glial TNFalpha. Science 2002;295:2282-2285. PMID: 11910117.

71. Yao JK, van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol 2004;59:297-326. PMID: 15006493.

72. Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen DC, et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl) 2009;204:177-184. PMID: 19139851.

73. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996;19:1-17. PMID: 9147491.

74. Rougemont M, Do KQ, Castagne V. New model of glutathione deficit during development: Effect on lipid peroxidation in the rat brain. J Neurosci Res 2002;70:774-783. PMID: 12444599.

75. McQuillen PS, Ferriero DM. Selective vulnerability in the developing central nervous system. Pediatr Neurol 2004;30:227-235. PMID: 15087099.

76. Berg D, Youdim MB, Riederer P. Redox imbalance. Cell Tissue Res 2004;318:201-213. PMID: 15365815.

77. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011;76:54-60. PMID: 20843610.

78. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Del'osso B, et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:1-4. PMID: 23085074.

79. Galecki P, Pietras T, Szemraj J, Florkowska K, Florkowski A, Zboralski K. [Functional polymorphism of manganese superoxide dismutase (MnSOD) gene correlates with schizophrenia in Polish population]. Pol Merkur Lekarski 2006;20:329-332. PMID: 16780268.

80. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995;270:296-299. PMID: 7569979.

81. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005;39:359-407. PMID: 16285865.

82. Dadheech G, Mishra S, Gautam S, Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008;50:16-20. PMID: 19771301.

83. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81:291-300. PMID: 16309894.

84. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003;117:85-88. PMID: 12581823.

85. Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, et al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009;60:87-93. PMID: 19776652.

86. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001;30:1191-1212. PMID: 11368918.

87. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994;12:1031-1040. PMID: 7514425.

88. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988;263:17205-17208. PMID: 3053703.

89. Shi ZZ, Osei-Frimpong J, Kala G, Kala SV, Barrios RJ, Habib GM, et al. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc Natl Acad Sci U S A 2000;97:5101-5106. PMID: 10805773.

90. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007;7:48-55. PMID: 17097347.

91. Leslie SW, Brown LM, Trent RD, Lee YH, Morris JL, Jones TW, et al. Stimulation of N-methyl-D-aspartate receptor-mediated calcium entry into dissociated neurons by reduced and oxidized glutathione. Mol Pharmacol 1992;41:308-314. PMID: 1347146.

92. Banday AA, Lokhandwala MF. Oxidative stress reduces renal dopamine D1 receptor-Gq/11alpha G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2. Am J Physiol Renal Physiol 2007;293:F306-F315. PMID: 17459951.

93. Steullet P, Neijt HC, Cuenod M, Do KQ. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006;137:807-819. PMID: 16330153.

94. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011;14:123-130. PMID: 20633320.

95. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A 2007;104:16621-16626. PMID: 17921251.

96. Rabinovic AD, Hastings TG. Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 1998;71:2071-2078. PMID: 9798932.

97. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006;79:586-592. PMID: 16909399.

98. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12:3721-3728. PMID: 11029642.

99. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001;15:287-310. PMID: 11463134.

100. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006;22:83-93. PMID: 16410648.

101. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008;3:e1944PMID: 18398470.

102. Dean OM, van den, Bush AI, Copolov DL, Ng F, Dodd S, et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009;16:2965-2976. PMID: 19689277.

103. Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ, et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 2010;177:575-585. PMID: 20566748.

104. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006;47:1-7. PMID: 16384802.

105. Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 2008;1142:133-158. PMID: 18990125.

106. Hruszkewycz AM. Lipid peroxidation and mtDNA degeneration. A hypothesis. Mutat Res 1992;275:243-248. PMID: 1383766.

107. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999;26:463-471. PMID: 9895239.

108. Chen JJ, Yu BP. Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radic Biol Med 1994;17:411-418. PMID: 7835747.

109. Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, et al. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 1997;80:685-696. PMID: 9276486.

110. Hazlett EA, Buchsbaum MS, Kemether E, Bloom R, Platholi J, Brickman AM, et al. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am J Psychiatry 2004;161:305-314. PMID: 14754780.

111. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 2011;15:2067-2079. PMID: 20673161.

112. Keating DJ. Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J Neurochem 2008;104:298-305. PMID: 17961149.

113. Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:118-124. PMID: 20570110.

114. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90:179-185. PMID: 17208413.

115. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:520-527. PMID: 20492850.

116. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005;57:1594-1596. PMID: 15953498.

117. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012;73:414-419. PMID: 22225599.

118. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361-368. PMID: 18436195.

119. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-2199. PMID: 18004285.

120. Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001;62:878-883. PMID: 11775047.

121. Zhang XY, Zhou DF, Su JM, Zhang PY. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol 2001;21:85-88. PMID: 11199954.

122. Zhou D, Zhang X, Su J, Nan Z, Cui Y, Liu J, et al. The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. Chin Med J (Engl) 1999;112:1093-1096. PMID: 11721446.

123. Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 2010;13:257-271. PMID: 19775502.

124. Sandyk R, Kanofsky JD. Vitamin C in the treatment of schizophrenia. Int J Neurosci 1993;68:67-71. PMID: 8063516.

125. Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic B, Buzina R. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990;28:959-966. PMID: 2275953.

126. Pitt B. Letter: Vitamin C and schizophrenia. Lancet 1974;2:1153-1154.

127. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005;182:494-498. PMID: 16133138.

128. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-671. PMID: 21641581.

129. Kato T, Mizoguchi Y, Monji A, Horikawa H, Suzuki SO, Seki Y, et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem 2008;106:815-825. PMID: 18429930.

130. Kato T, Monji A, Hashioka S, Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res 2007;92:108-115. PMID: 17363222.

131. Hou Y, Wu CF, Yang JY, He X, Bi XL, Yu L, et al. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1523-1528. PMID: 16806626.

132. Kowalski J, Labuzek K, Herman ZS. Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-alpha and nitric oxide by rat microglial cells. Neurochem Int 2003;43:173-178. PMID: 12620286.

133. Labuzek K, Kowalski J, Gabryel B, Herman ZS. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol 2005;15:23-30. PMID: 15572270.

134. Halim ND, Weickert CS, McClintock BW, Weinberger DR, Lipska BK. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004;29:1063-1069. PMID: 15010699.

135. Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010;479:317-320. PMID: 20561936.

136. Park SW, Lee CH, Lee JG, Kim LW, Shin BS, Lee BJ, et al. Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neurosci Res 2011;69:283-290. PMID: 21238512.

137. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 2005;81:572-580. PMID: 15948179.

138. Dakhale G, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004;49:205-209. PMID: 15154399.

139. Zhang XY, Zhou DF, Shen YC, Zhang PY, Zhang WF, Liang J, et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012;62:1928-1934. PMID: 22227558.

140. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003;23:128-131. PMID: 12640213.

141. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81:291-300. PMID: 16309894.